# Nuclide record psma-1007-f18 (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/psma-1007-f18/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "psma-1007-f18" ;
  schema:name "PSMA-1007 F-18"@en ;
  schema:alternateName "Prostalumin"@en ;
  schema:description "PSMA-1007 is a fluorine-18 PSMA PET tracer from ABX in Germany, widely used in Europe for prostate cancer staging because little of it reaches the bladder, and in a phase 3 trial registered by its maker."@en ;
  schema:url <https://nuclide.cc/drugs/psma-1007-f18/> ;
  schema:dateModified "2026-10-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=PSMA-1007%20F-18>, <https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107378> ;
  nuclide:status "phase-3" ;
  nuclide:tag "pipeline", "ctgov-ingest" ;
  nuclide:modality "PSMA-targeted PET radiotracer, fluorine-18" ;
  nuclide:related <https://nuclide.cc/isotopes/f-18/>, <https://nuclide.cc/isotopes/ga-68/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:technologies <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/technologies/pet/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:companies <https://nuclide.cc/companies/abx-advanced-biochemical-compounds/> ;
  nuclide:trials <https://nuclide.cc/trials/nct06122584/> .